SMFM 27th Annual Meeting 2007
view the interview video: Fetal Congenital Heart Block
OBJECTIVE: Anti-Ro/La-associated congenital heart block (CHB) carries a 20% mortality. Nearly all survivors require pacemakers. Once established 3rd degree block is not reversible. We initiated the PRIDE Study to evaluate an early marker of cardiac injury prior to permanent scarring, the "mechanical PR interval".
STUDY DESIGN: Women with anti-Ro/La antibodies had fetal echocardiograms weekly from 16-26 weeks, then biweekly from 26-34 weeks. Mechanical PR interval >150 msec (mean + 3 SD) was considered abnormal, consistent with 1st degree block. All patients had anti-Ro titer >30 EU (normal <19); mean titer was 11,000. Mothers were excluded if taking >10 mg/day prednisone.
RESULTS: We enrolled 127 fetuses, with 94 delivered, 7 still pregnant, & 26 dropouts. There were 88 fetuses (91%) with normal PR intervals throughout. CHB occurred in 3 of 16 mothers with a previous CHB child (19%) and 3 of 70 with no previous CHB (4%). Three fetuses had 3rd degree block, all onset <23 weeks. Two terminated for hydrops, both developed hydrops despite maternal dexamethasone within 2 weeks of an echocardiogram showing normal PR interval, but with tricuspid regurgitation. The other is alive at 12 months of age with a pacemaker. There were 3 fetuses with 1st degree block detected by echo. Two of these were detected at 18-22 weeks and resolved with 3-7 days of dexamethasone 4 mg po qd. Both had normal EKG at birth. The third had normal PR through 30 wk and was born at 32 wk with 1st degree block on EKG that has persisted to 3 years.
CONCLUSION: 1st degree fetal heart block may be reversible with dexamethasone, supporting the utility of close monitoring, especially given the high recurrence rate substantiated in this study. Advanced block and cardiomyopathy can occur within 1 week of a normal echocardiogram, so even weekly evaluation may not be sufficient to detect early onset of disease. Third degree block is not reversible despite early intervention. Either a reliable marker of early disease, or a safe and economical method of prophylaxis, is needed.
Study shows a healthy prenatal diet could be upstream obesity prevention strategy
December 26th 2024"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Early pregnancy cannabis use high in states with recreational legalization
November 11th 2024A population-based time-series analysis California before, during and after legalization show a rising trend in women using cannabis while pregnancy especially when the state has legalized the drug.
Read More
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More